GILD Gilead Sciences Dashboard

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

Company profile

Ticker

GILD

Exchange

NASDAQ

Website

www.gilead.com

CEO

Daniel O'Day

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Exelixis • Seagen ...

SEC CIK

0000882095

Corporate docs

Articles of Incorporation & Bylaws

IRS number

943047598

GILD stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Understanding Gilead Sciences's Unusual Options Activity

30 Jul 21

On Friday, shares of Gilead Sciences (NASDAQ:GILD) saw unusual options activity. After the option alert, the stock price moved down to $68.66.

RBC Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $84

30 Jul 21

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Outperform and raises the price target from $81 to $84.

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs

30 Jul 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)

Gilead Sciences Exceeds Expectations As Remdesivir Success Cushions Slump In HIV Franchise

30 Jul 21

SVB Leerink Maintains Outperform on Gilead Sciences, Raises Price Target to $77

30 Jul 21

Press releases

Pro users get this 30m faster

Gilead Sciences Announces Second Quarter 2021 Financial Results

29 Jul 21

Second Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury Biktarvy Sales Increased 24% Year-Over-Year Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for

Prioritizing the Needs of the Black LGBTQ+ Community in an Innovative HIV Trial

27 Jul 21

Northampton, MA--News Direct--Dr. Theo Hodge, a physician and infectious disease expert with the Washington Health Institute in Washington, D.C., is all too familiar with the disproportionate impact HIV has on the Black

BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

19 Jul 21

-- Deal Strengthens BioNTech's Cell Therapy Pipeline By Accelerating Individualized Solid Tumor Neoantigen TCR Cell Therapy Research and Development Program and Adding Manufacturing Footprint in North America -- --

Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults

17 Jul 21

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

17 Jul 21

Calendar

6 May 21

30 Jul 21

31 Dec 21

Financial summary

Financial statements Chart GILD financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	4.07B	4.07B	4.07B	4.07B	4.07B	4.07B
Cash burn (monthly)	644M	498.83M	(positive/no burn)	(positive/no burn)	(positive/no burn)	(positive/no burn)
Cash used (since last report)	2.57B	1.99B	n/a	n/a	n/a	n/a
Cash remaining	1.49B	2.07B	n/a	n/a	n/a	n/a
Runway (months of cash)	2.3	4.2	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

GILD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
24 Jul 21	Mercier Johanna	Common Stock	Payment of exercise	Dispose F	No	No	69.02	3,425	236.39K	12,148
24 Jul 21	Mercier Johanna	Common Stock	Option exercise	Aquire M	No	No	0	7,505	0	15,573
24 Jul 21	Mercier Johanna	RSU Common Stock	Option exercise	Dispose M	No	No	0	7,505	0	39,930
29 Jun 21	Lofton Kevin E	Phantom Stock Common Stock	Grant	Aquire A	No	No	0	30.133	0	2,913.096
15 Jun 21	Rodriguez Javier	Common Stock	Option exercise	Aquire M	No	No	0	1,838	0	1,838
15 Jun 21	Rodriguez Javier	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,838	0	2,223
10 Jun 21	Dickinson Andrew D	Common Stock	Payment of exercise	Dispose F	No	No	69.29	1,605	111.21K	36,971
10 Jun 21	Dickinson Andrew D	Common Stock	Option exercise	Aquire M	No	No	0	3,646	0	38,576
10 Jun 21	Dickinson Andrew D	RSU Common Stock	Option exercise	Dispose M	No	No	0	3,646	0	39,290
12 May 21	Welters Anthony	NQSO Common Stock	Grant	Aquire A	No	No	67.45	14,665	989.15K	14,665

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

GILD institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

76.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1525	1527	-0.1%
Opened positions	140	210	-33.3%
Closed positions	142	185	-23.2%
Increased positions	614	500	+22.8%
Reduced positions	588	673	-12.6%

13F shares	Current	Prev Q	Change
Total value	62.24B	56.48B	+10.2%
Total shares	963.34M	969.54M	-0.6%
Total puts	22.37M	25.87M	-13.5%
Total calls	24.21M	21.24M	+14.0%
Total put/call ratio	0.9	1.2	-24.1%

Largest owners	Shares	Value	Change
BLK Blackrock	124.72M	$8.06B	+12.2%
Capital Research Global Investors	122.61M	$7.92B	+0.8%
Vanguard	104.26M	$6.74B	+1.4%
STT State Street	53.47M	$3.46B	-3.1%
Capital International Investors	40.03M	$2.59B	-14.0%
Capital World Investors	35.08M	$2.27B	-9.0%
Geode Capital Management	20.67M	$1.33B	+3.0%
Dodge & Cox	18.46M	$1.19B	+7.9%
NTRS Northern Trust	15.13M	$977.8M	-0.8%
BK Bank Of New York Mellon	13.06M	$843.78M	-5.4%

Largest transactions	Shares	Bought/sold	Change
BLK Blackrock	124.72M	+13.54M	+12.2%
Norges Bank	0	-13.17M	EXIT
Capital International Investors	40.03M	-6.52M	-14.0%
Susquehanna International	3.2M	-5.51M	-63.3%
Nuveen Asset Management	8.72M	+3.92M	+81.6%
Capital World Investors	35.08M	-3.45M	-9.0%
Arrowstreet Capital, Limited Partnership	0	-3.08M	EXIT
BEN Franklin Resources	4.22M	-3.01M	-41.6%
Sarissa Capital Management	2.7M	+2.7M	NEW
BAC Bank Of America	8.01M	+2.67M	+50.1%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Gene Biotherapeutics • Spectrum Pharmaceuticals • Idera Pharmaceuticals • Exelixis • Aradigm • Cymabay Therapeutics • Inovio Pharmaceuticals • Viracta Therapeutics • Arena Pharmaceuticals • Ziopharm Oncology

Risks

Certain of our products subject us to additional or heightened risks.
Our success depends on developing and commercializing new products or expanding the indications for existing products.
We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.
We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers.
Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.
We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.
We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.
Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.
We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry.
We are subject to risks if significant safety issues arise for our marketed products or our product candidates.
Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.
We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations.
Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the recent COVID-19 outbreak.
We face risks associated with our global operations.
We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.
Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us.
We are dependent on information technology systems, infrastructure and data, which may be subject to cyberattacks, security breaches and legal claims.
We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.
Changes in our effective income tax rate could reduce our earnings.

Management Discussion

Total product sales increased by 16% to $6.3 billion for the first quarter of 2021, compared to $5.5 billion for the same period in 2020, primarily due to sales of Veklury, our FDA-approved treatment for hospitalized patients with COVID-19. The first quarter of 2021 reflects growth in Cell Therapy, Trodelvy and hepatitis B virus (“HBV”)/hepatitis delta virus (“HDV”). We obtained Trodelvy through the acquisition of Immunomedics, Inc. (“Immunomedics”) in the fourth quarter of 2020. The increases were partially offset by lower HIV product sales primarily due to the continued generic competition following the October 2020 loss of exclusivity of Truvada and Atripla in the United States, in addition to higher channel inventory purchases in the first quarter of 2020 due to the COVID-19 pandemic. The decline in HCV sales was mainly driven by lower patient starts due to the continued impact of the pandemic.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abandonment, Argument, BMS, breakout, bulevirtide, Cabaret, calendar, CFCA, CODM, conditionally, constitute, content, convenience, costly, counterclaim, counterpart, Defense, delta, disaggregated, Division, Dohme, elvitegravir, enjoined, epidermal, Eshhar, factor, Fe, GAAP, German, GmbH, HDV, healthier, hepcludex, hormone, India, injectable, intervention, islatravir, job, Judicial, knowable, KR, Landgericht, liable, life, lot, Master, Mexico, misalignment, MYR, NaN, nonrecurring, NuCana, Partly, plc, preliminarily, Presidential, putative, Reciprocally, referenced, refinance, repay, rest, risky, sacituzumab, Santa, Sharp, shelter, shipment, stream, suit, tightened, TMFPA, transcriptase, translocation, tribunal, Unlimited, unresectable, urothelial, vaccination, voluntarily, waiver, website, written, Zelig

Removed: abroad, acute, add, affirming, agonist, Alameda, Allergy, antibody, appointment, ASU, attempt, banc, BPD, broader, CAFC, CEO, certiorari, children, Circuit, Clarifying, close, closed, Conference, controlling, cooperated, copay, coupon, cure, declared, declination, deliver, demonstrated, designation, dismissing, DNA, emerge, emergency, employer, en, enable, evasion, expand, extended, FASB, Forty, functional, GILTI, heading, immune, implemented, inflammatory, informed, invalidated, joined, laid, leukemia, living, managed, mantle, Mateo, methodology, modified, monoclonal, myelodysplastic, myeloid, NDA, Notwithstanding, older, opinion, originally, pause, placebo, planned, postponement, preliminary, presenting, President, prioritization, profile, rapidly, recognition, rehearing, released, reputational, request, resource, response, responsible, retaliation, retention, retrospective, retrospectively, rheumatoid, San, sclerosing, shareholder, shorten, simplify, solid, specialty, spread, strive, study, submission, supplemental, supporting, sustainable, switch, switching, targeting, Topic, transform, transformative, treated, treating, Trump, ulcerative, urgent, vacated, vesatolimod, Vice, voluntary, write

From filing 10-Q 2021 Q1